Cancer Supportive Care Drugs Market, Analysis and Forecast to 2031, By Type, By Application, By Distribution Channel
- Published Date : 2024-05-27
- Pages : 100
- Report Id : 40390
- Categories : Healthcare
This report describes the global market size of Cancer Supportive Care Drug Market from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and its expected to grow with a CAGR of 2.2% from 2024 to 2031.
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Cancer Supportive Care Drug Market estimated at US $XX billion in the year 2022, is projected to reach a revised size of US$ million by 2031, growing at a CAGR of 2.2% during the forecast period 2024-2031. North American market for Cancer Supportive Care Drug Market is estimated to increase from $million in 2023 to reach $ million by 2031, at a CAGR of % during the forecast period of 2024 through 2031.
For geography segment, regional supply, demand, major players, price is presented from 2019 to 2031. This report cover following regions:
North America
Asia-Pacific
Europe
Middle East and Africa
South America
The key countries for each regions are also included such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
For competitor segment, the report include global key players of Cancer Supportive Care Drug Market as well as some small players. The information for each competitor include:
Company Profile
Main Business Information
SWOT Analysis
Sales Volume, Revenue, Price and Gross Margin
Market Share
By Type
Erythropoiesis Stimulating Agents
Granulocyte Colony Stimulating Factors
Antiemetics
Bisphosphonates
Opioids
Nonsteroidal Anti Inflammatory Drugs
Others
In 2023,the cancer supportive care drugs market was categorized into several segments, including erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (non-steroidal anti-inflammatory drugs), and others. Among these, the granulocyte colony-stimulating factors (G-CSFs) segment emerged as the largest contributor to market revenue and is projected to maintain its dominance throughout the forecast period. The pivotal role of G-CSFs lies in supporting cancer patients by stimulating the production of white blood cells, crucial for preventing infections during chemotherapy, thereby propelling the growth of this segment.
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Stomach Cancer
Others
In 2023,The cancer supportive care drugs market is divided into segments including breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others. Among these, the breast cancer segment held the largest market share in terms of revenue in 2022 and is projected to continue leading during the forecast period. The increasing prevalence of breast cancer and the growing adoption of various treatments, often associated with side effects, drive the demand for cancer supportive care drugs in this segment.
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
In 2023,The cancer supportive care drugs market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.
the drug stores & retail pharmacies segment held the largest market share in terms of revenue, a trend expected to persist throughout the forecast period. This dominance is credited to several factors, with convenience and widespread accessibility being prominent among them. The ubiquitous presence of drug stores and retail pharmacies greatly enhances patient convenience, thereby solidifying their preference for these outlets.
Company-
Teva Pharmaceutical Industries Ltd.
Merck & Co.
Pfizer Inc.
Amgen Inc.
Helsinn Healthcare SA
Hoffmann-La Roche AG
Baxter International Inc.
Novartis AG
Johnson & Johnson
Heron Therapeutics, Inc.
Please ask for sample pages for full companies list
Base Year: 2023
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2031
Any special requirements about this report, please let us know and we can provide custom report.
TABLE OF CONTENTS
Market Taxonomy
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis and Recommendations
1.3. RA Analysis and Recommendations
2. Market Introduction
2.1. Market Definition
3. Market Background
3.1. Parent/Associated Market Overview
3.1.1. Cancer Supportive Care Drugs Outlook
3.1.2. Cancer Supportive Care Drugs Overview
3.2. Effect of Covid-19 Impact
3.3. Effect of Russia-Ukraine Impact
3.4. Macro-Economic Overview
3.4.1. GDP Growth
3.4.2. Retail Industry Growth
3.5. Pricing Analysis
3.6. Challenges related to adoption of Cancer Supportive Care Drugs
3.7. Regulations of Cancer Supportive Care Drugs
3.8. Forecast Factors: Relevance and Impact
3.9. Market Dynamics
3.9.1. Drivers
3.9.2. Restraints
3.9.3. Opportunity
3.9.4. Trends
3.9.5. SWOT Analysis
4. Market Forecast
4.1. Market Value Projections
4.2. Market Size Projections
4.3. Y-o-Y Projections
4.4. Absolute Opportunity Analysis
5. Global Cancer Supportive Care DrugsValue Chain Analysis
5.1. Cancer Supportive Care DrugsValue Chain
5.1.1. List of Raw Material Suppliers
5.1.2. List of Cancer Supportive Care DrugsManufacturer
5.1.3. List of Segment
6. Global Cancer Supportive Care Drugs Analysis By Product
6.1. Introduction
6.1.1. Market Value Share Analysis By Product
6.1.2. Y-o-Y Growth Analysis By Product
6.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Product
6.3. Market Attractiveness Analysis By Product
7. Global Cancer Supportive Care Drugs Analysis By Aplication
7.1. Introduction
7.1.1. Market Value Share Analysis By Aplication
7.1.2. Y-o-Y Growth Analysis By Aplication
7.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Aplication
7.3. Market Attractiveness Analysis By Aplication
8. Market Structure Analysis
8.1. Market Analysis by Tier of Companies
8.1.1. By Large, Medium, and Small
8.2. Market Concentration
8.2.1. By Top 5 and by Top 10
8.3. Type ion Capacity Share Analysis
8.3.1. By Large, Medium, and Small
8.3.2. By Top 5 and Top 10
8.4. Technology Roadmap
9. Competition Analysis
9.1. Competition Dashboard
9.2. Company Profiles (15 Companies)
9.2.1. Teva Pharmaceutical Industries Ltd.
9.2.1.1. Overview
9.2.1.2. Product Portfolio
9.2.1.3. Financial Overview
9.2.2. Merck & Co.
9.2.2.1. Overview
9.2.2.2. Product Portfolio
9.2.2.3. Financial Overview
9.2.3. Pfizer Inc.
9.2.3.1. Overview
9.2.3.2. Product Portfolio
9.2.3.3. Financial Overview
9.2.4. Amgen Inc.
9.2.4.1. Overview
9.2.4.2. Product Portfolio
9.2.4.3. Financial Overview
9.2.5. Helsinn Healthcare SA
9.2.5.1. Overview
9.2.5.2. Product Portfolio
9.2.5.3. Financial Overview
9.2.6. Hoffmann-La Roche AG
9.2.6.1. Overview
9.2.6.2. Product Portfolio
9.2.6.3. Financial Overview
9.2.7. Baxter International Inc.
9.2.7.1. Overview
9.2.7.2. Product Portfolio
9.2.7.3. Financial Overview
9.2.8. Novartis AG
9.2.8.1. Overview
9.2.8.2. Product Portfolio
9.2.8.3. Financial Overview
9.2.9. Johnson & Johnson
9.2.9.1. Overview
9.2.9.2. Product Portfolio
9.2.9.3. Financial Overview
9.2.10. Heron Therapeutics, Inc.
9.2.10.1. Overview
9.2.10.2. Product Portfolio
9.2.10.3. Financial Overview
9.2.11. COMPANY11
9.2.11.1. Overview
9.2.11.2. Product Portfolio
9.2.11.3. Financial Overview
9.2.12. COMPANY12
9.2.12.1. Overview
9.2.12.2. Product Portfolio
9.2.12.3. Financial Overview
9.2.13. COMPANY13
9.2.13.1. Overview
9.2.13.2. Product Portfolio
9.2.13.3. Financial Overview
9.2.14. COMPANY14
9.2.14.1. Overview
9.2.14.2. Product Portfolio
9.2.14.3. Financial Overview
9.2.15. COMPANY15
9.2.15.1. Overview
9.2.15.2. Product Portfolio
9.2.15.3. Financial Overview
10. Global Cancer Supportive Care Drugs Analysis By Region
10.1. Introduction
10.1.1. Market Value Share Analysis By Region
10.1.2. Y-o-Y Growth Analysis By Region
10.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Region
10.2.1. North America
10.2.2. Middle East and Africa
10.2.3. South America
10.2.4. Asia-Pacific
10.2.5. Others
10.3. Current Market Size (USD Mn) Forecast 2023-2030 By Region
10.3.1. North America
10.3.2. Middle East and Africa
10.3.3. South America
10.3.4. Asia-Pacific
10.3.5. Others
10.4. Market Attractiveness Analysis By Region
11. North America Cancer Supportive Care Drugs Analysis
11.1. Introduction
11.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
11.2.1. U.S.
11.2.2. Canada
11.2.3. Mexico
11.2.4. Rest of North America
11.3. Current Market Size (USD Mn) Forecast 2023-2030 By Country
11.3.1. U.S.
11.3.2. Canada
11.3.3. Mexico
11.3.4. Rest of North America
11.4. Historical Market Size (USD Mn) Analysis 2018-2022 By Product
11.5. Current Market Size (USD Mn) Forecast 2023-2030 By Product
11.6. Historical Market Size (USD Mn) Analysis 2018-2022 By Aplication
11.7. Current Market Size (USD Mn) Forecast 2023-2030 By Aplication
12. South America Cancer Supportive Care Drugs Analysis
12.1. Introduction
12.2. Regional Pricing Analysis
12.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
12.3.1. Brazil
12.3.2. Argentina
12.3.3. Rest of South America
12.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of South America
12.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Product
12.6. Current Market Size (USD Mn) Forecast 2023-2030 By Product
12.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Aplication
12.8. Current Market Size (USD Mn) Forecast 2023-2030 By Aplication
13. Europe Cancer Supportive Care Drugs Analysis
13.1. Introduction
13.2. Regional Pricing Analysis
13.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
13.3.1. Germany
13.3.2. Italy
13.3.3. France
13.3.4. Spain
13.3.5. U.K.
13.3.6. Rest of Europe
13.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
13.4.1. Germany
13.4.2. Italy
13.4.3. France
13.4.4. Spain
13.4.5. U.K.
13.4.6. Rest of Europe
13.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Product
13.6. Current Market Size (USD Mn) Forecast 2023-2030 By Product
13.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Aplication
13.8. Current Market Size (USD Mn) Forecast 2023-2030 By Aplication
14. Middle East and Africa Cancer Supportive Care Drugs Analysis
14.1. Introduction
14.2. Regional Pricing Analysis
14.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
14.3.1. Saudi Arabia
14.3.2. U.A.E.
14.3.3. South Africa
14.3.4. Turkey
14.3.5. Rest of Middle East and Africa
14.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
14.4.1. Saudi Arabia
14.4.2. U.A.E.
14.4.3. South Africa
14.4.4. Turkey
14.4.5. Rest of Middle East and Africa
15. Asia-Pacific Cancer Supportive Care Drugs Analysis
15.1. Introduction
15.2. Regional Pricing Analysis
15.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
15.3.1. China
15.3.2. India
15.3.3. Japan
15.3.4. South Korea
15.3.5. Singapore
15.3.6. Australia and New Zealand
15.3.7. Rest of Asia-Pacific
15.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
15.4.1. China
15.4.2. India
15.4.3. Japan
15.4.4. South Korea
15.4.5. Singapore
15.4.6. Australia and New Zealand
15.4.7. Rest of Asia-Pacific
i. Research Methodology
ii. Assumptions & Acronyms
LIST OF FIGURES
Figure 01: Global Cancer Supportive Care Drugs, BPS Analysis, By Product , 2018(H), 2023(E) & 2030(F)
Figure 02: Global Cancer Supportive Care Drugs, Y-O-Y Growth, By Product , 2020(A) - 2030(F)
Figure 03: Global Cancer Supportive Care Drugs Attractiveness Analysis, By Product (2020)
Figure 04: Global Cancer Supportive Care Drugs, BPS Analysis, By Aplication , 2018(H), 2023(E) & 2030(F)
Figure 05: Global Cancer Supportive Care Drugs, Y-O-Y Growth, By Aplication , 2018(H) - 2030(F)
Figure 06: Global Cancer Supportive Care Drugs Attractiveness Analysis, By Aplication
Figure 07: Global Cancer Supportive Care Drugs, Value Analysis, By Product , 2018(H)-2030(F)
Figure 08: Global Cancer Supportive Care Drugs, Value Analysis, by Material , 2018(H)-2030(F)
Figure 09: Global Cancer Supportive Care Drugs, BPS Analysis, by Region, 2018(H), 2023(E) & 2030(F)
Figure 10: Global Cancer Supportive Care Drugs, Y-O-Y Growth, by Region, 2018(H) - 2030(F)
Figure 11: Global Cancer Supportive Care Drugs Attractiveness Analysis, by Region
Figure 12: North America Cancer Supportive Care Drugs Value (USD Mn Forecast, 2018 – 2022
Figure 13: North America Cancer Supportive Care Drugs Value (USD Mn Forecast, 2023 – 2030
Figure 14: South America Cancer Supportive Care Drugs Value (USD Mn) Forecast, 2018 – 2022
Figure 15: South America Cancer Supportive Care Drugs Value (USD Mn) Forecast, 2023 – 2030
Figure 16: Europe Cancer Supportive Care Drugs Value (USD Mn) Forecast, 2018 – 2022
Figure 17: Europe Cancer Supportive Care Drugs Value (USD Mn) Forecast, 2023 – 2030
Figure 18: Middle East and Africa Cancer Supportive Care Drugs Value (USD Mn) Forecast, 2018 – 2022
LIST OF TABLES
Table 01: Global Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Product , 2018(H) – 2030(F)
Table 02: Global Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Aplication , 2018(H) – 2030(F)
Table 03: Global Cancer Supportive Care Drugs Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 04: North America Cancer Supportive Care Drugs Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 05: North America Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Product , 2018(H) – 2030(F)
Table 06: North America Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Aplication , 2018(H) – 2030(F)
Table 07: South America Cancer Supportive Care Drugs Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 08: South America Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Product , 2018(H) – 2030(F)
Table 09: South America Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Aplication , 2018(H) – 2030(F)
Table 10: Europe Cancer Supportive Care Drugs Value (USD Mn) and Forecast, by Country, 2018(H) – 2030(F)
Table 11: Europe Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Product , 2018(H) – 2030(F)
Table 12: Europe Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Aplication EndUser, 2018(H) – 2030(F)
Table 13: Middle East and Africa Cancer Supportive Care Drugs Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 14: Middle East and Africa Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Product , 2018(H) – 2030(F)
Table 15: Middle East and Africa Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Aplication , 2018(H) – 2030(F)
Table 16: Asia-Pacific Cancer Supportive Care Drugs Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 17: Asia-Pacific Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Product , 2018(H) – 2030(F)
Table 18: Asia-Pacific Cancer Supportive Care Drugs Value (USD Mn) Forecast, By Aplication , 2018(H) – 2030(F)"
Direct Purchase
Your perfect start with Stats And ResearchWant to customize this report?
This report can be customized according to your requirements. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
Avail PDF Sample Reports
You may also be lnterested in..
Stats And Research Copyright © 2024 .